Halozyme Therapeutics, Inc. (HALO)
-NasdaqGS | Prev Close: | 6.32 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | 8.28 x 500 |
|---|
| 1y Target Est: | 8.14 |
|---|
| Beta: | 1.45 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 3.86 - 9.92 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,344,240 |
|---|
| Market Cap: | 710.47M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Halozyme Firing On All Cylinders - Should Investors Get Behind The Wheel?at Seeking Alpha(Mon, Jun 17)
- Halozyme Therapeutics Breaks Below 200-Day Moving Average - Notable for HALOat Forbes(Wed, Jun 5)
- Spectrum Pharma names Gustafson as new CFOAP(Wed, Jun 5)
- Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic CancerPR Newswire(Mon, Jun 3)
- 3 Stocks to Watch Ahead of ASCOat Motley Fool(Tue, May 28)
- HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, May 24)
- Ahead Of The Trend: 7 Rallying Stocks With Institutional Selling And Short Increasesat TheStreet(Thu, May 23)
- CFO Moves: KeyCorp, Huntington Bancshares, Halozymeat The Wall Street Journal(Thu, May 23)
- Halozyme names David Ramsay as CFOAP(Thu, May 23)
- The Coming Diabetes Warsat Motley Fool(Thu, May 23)
- Halozyme Therapeutics Names David A. Ramsay Chief Financial OfficerPR Newswire(Thu, May 23)
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue, May 21)
- Baxter Receives Marketing Authorization for HyQvia in European UnionBusiness Wire(Tue, May 21)
- 3 Humongous Health-Care Stocks This Weekat Motley Fool(Sat, May 18)
- HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhEDGAR Online(Fri, May 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 15.21 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.57 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery ...
View More